Oncology companies develop therapies, diagnostics and technologies that support the detection, monitoring and treatment of cancer. The sector is one of the largest and most active areas of biotechnology and pharmaceutical innovation.
This category includes companies working on:
Browse 291 UK oncology companies below.
Dendritic cell biology platform for cancer and autoimmune therapies
Adendra Therapeutics is a discovery-stage biotechnology company developing small molecule and biologic medicines targeting dendritic cell biology for the treatment of solid tumours and autoimmune diseases. The company's approach is based on research into how dendritic cells regulate adaptive immune responses to cell…
Academic cancer research institute and drug discoverer
The Institute of Cancer Research (ICR) is an independent research institute and member institution of the University of London, specialising in cancer biology, drug discovery, genetics, and precision radiotherapy. Working closely with the Royal Marsden NHS Foundation Trust, the ICR has discovered cancer medicines…
Biotech venture builder co-creating and scaling drug discovery companies
Molecule to Medicine (MTM) is a biotech venture builder that co-creates, builds, and scales drug discovery companies within a shared operational ecosystem, combining drug discovery expertise with shared infrastructure to enable rapid company formation. UK operations are based at Milton Park, Abingdon, with a further…
Multiomics platform for cancer biomarker discovery and diagnostics
Tagomics is a Cambridge-based biotech developing a multiomics platform for disease biomarker discovery and diagnostics. Its platform integrates genomics, epigenomics and fragmentomics with advanced bioinformatics and machine learning to identify disease-associated DNA markers from blood and other biological sources.…
CASPAROV AI platform for targets in heterogeneous cancers
Enedra Therapeutics develops targeted cancer medicines designed to address genetic diversity within solid tumours, a major cause of treatment resistance. Its CASPAROV platform combines cancer genomics, AI and functional biology to identify survival mechanisms shared across heterogeneous tumour cells. These convergent…
G-quadruplex-targeting medicines for precision cancer treatment
Genome Therapeutics is a biotechnology company developing cancer medicines that target G-quadruplex DNA structures associated with tumour biology. Its approach builds on research into non-canonical DNA folding and how these structures influence gene regulation and cancer cell vulnerabilities. The company develops…
Full-service CRO for Phase I–IV pharmaceutical and device trials
Clinicology is a contract research organisation providing clinical trial management services to pharmaceutical, biotechnology, and medical device companies. Services span site startup, monitoring, project management, regulatory submissions, patient recruitment, medical monitoring, medical writing, and…
Global generics and specialty pharmaceutical manufacturer headquartered in London
Hikma Pharmaceuticals is a multinational pharmaceutical company developing, manufacturing and marketing generic, specialty and branded medicines across injectable, oral and respiratory dosage forms. The company's portfolio spans oncology, cardiovascular, respiratory, pain management and other therapeutic areas,…
AI platform targeting chromosomal instability across cancer
Tailor Bio is a Cambridge-based biotechnology company developing an AI-driven precision medicine platform for cancers with chromosomal instability, a genomic phenomenon present in over 80% of all cancers. Founded from research originating at the Cancer Research UK Cambridge Institute, the company develops both…
E3 ligase inhibitors stabilising tumour suppressor proteins
Outrun Therapeutics is a preclinical drug discovery company developing small molecule inhibitors of E3 ligase enzymes to stabilise tumour suppressor and other disease-relevant proteins. Its proprietary platform has been used to profile over 45 E3 ligases across oncology, cardiovascular, neurological, and autoimmune…
CSF-1R antibody therapy for tenosynovial giant cell tumour
SynOx Therapeutics is a late-stage biopharmaceutical company developing emactuzumab, a humanised monoclonal antibody targeting CSF-1R, for the treatment of tenosynovial giant cell tumour and other macrophage-driven conditions. Emactuzumab was licensed from Roche and inhibits the CSF-1 receptor to deplete…
Global pharmaceutical company developing medicines across major disease areas
AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines. Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines. The company…
Cancer immunotherapies targeting novel antigens from the dark genome
Enara Bio is a clinical-stage biopharmaceutical company developing cancer immunotherapies directed against Dark Antigens, a class of cancer-specific targets derived from previously uncharted genomic dark matter. Its platform integrates bioinformatics, immunopeptidomics, and immunology to discover and validate novel…
RNA trans-splicing gene therapies for aggressive cancers
Spliceor is a University of Cambridge spinout developing RNA trans-splicing gene therapies for aggressive cancers. Its platform is designed to produce therapeutic messenger RNA selectively in targeted cells by joining segments from different RNA molecules. Machine learning helps refine the constructs and optimise…
Immune cell separation and expansion platform for cell therapies
CoED Biosciences is a biotech developing the Column of Expansion and Differentiation (CoED) platform, a consumable device integrating immune cell separation, functionalisation, and expansion in a single workflow. The system exploits the natural migratory behaviour of immune cells across membranes, replacing…
Small molecule GPR65 inhibitors restoring immune response in solid tumours
Pathios Therapeutics is a clinical-stage drug discovery company developing small molecule inhibitors of GPR65, a pH-sensing G protein-coupled receptor that drives immunosuppressive polarisation of tumour-associated macrophages in the acidic tumour microenvironment. By blocking GPR65, Pathios aims to restore…
Precision oncology drugs and vaccines for cold tumours
IngenOx Therapeutics Limited is a clinical-stage biopharmaceutical company developing precision oncology drugs and cancer vaccines for difficult-to-treat tumours. The company serves oncology patients and clinical development partners through a pipeline spanning small molecule immunomodulators, PRMT5 inhibition and…
Specialist pharma acquiring and developing rare disease therapeutics
Ambrose Healthcare is a UK specialist pharmaceutical company developing treatments for rare diseases and patients in hospital and specialist care settings. The company builds its pipeline through the acquisition and licensing of late-stage clinical assets with existing human safety and efficacy data, targeting…
Targeted radiotheranostics for treatment-resistant solid tumours
Nuclide Therapeutics is a King's College London spin-out developing targeted radiopharmaceuticals for treatment-resistant solid tumours. Its radiotheranostic approach uses tumour-binding molecules labelled with diagnostic or therapeutic radionuclides to identify and attack cancer cells. Lead programmes target ALDH1A1…
Preclinical inhibitors of Notch and Mastermind cancer signalling pathways
Anastasis Biotec is a preclinical biotechnology company developing targeted inhibitors of cancer signalling pathways, with a focus on the Notch pathway and its transcriptional co-activator Mastermind. These pathways help drive tumour growth and the survival of cancer stem cells. The company is developing peptide-based…